NCI Corner

Articles from the US National Cancer Institute about issues relevant to the field of thoracic oncology.

NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

In October 2017, the United States National Cancer Institute (NCI) launched a major effort to expand the discovery and validation of predictive biomarkers on...

Discussing ALCHEMIST with Shakun Malik, MD

Patients with completely resected early-stage non-small cell lung cancer (NSCLC) have approximately a 50% chance of experiencing disease recurrence following standard treatment. In 2014,...

NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

Investigators at the National Cancer Institute (NCI) compared the transcriptional profiles of lung cancers from African American patients to those from white patients and...

NCI Corner – Interview with Matthew Holderfield, PhD

NCI to Team Up with Cancer Research UK and the Cancer Research Technology Pioneer Fund on RAS Research On April 19, 2017, Cancer Research UK...

NCI Corner – Interview with Shakun Malik, MD

By Erik J. Maclaren, PhD 2017 Mesothelioma Clinical Trials Planning Meeting Malignant mesothelioma is one of the most difficult cancers to control using existing therapies. Due...

NCI Formulary Holds Promise to Speed Clinical Trials

By Erik T. MacLaren, PhD On January 11, the National Cancer Institute (NCI) launched a virtual agent formulary (NCI Formulary): a new public-private partnership designed...

Tools for Smoking Cessation

By Erik J. MacLaren, PhD Scott Gottlieb, MD, Commissioner of the U.S. Food and Drug Administration, said in a recent speech, “There’s probably no single...

Lung Cancer and Smoking Cessation: Opportunities for Progress

By Stephanie R. Land, PhD Tobacco cessation assistance, imperative for tobacco users who seek medical care,1 takes on even greater urgency for individuals who are...

Meeting News